Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423182 | 1.00 | KDM4E (0.53) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL26617566 | 0.90 | KDM4E (0.53) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL30681975 | 0.90 | KDM4E (0.53) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL30549003 | 0.86 | CFTR (0.52) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL31423261 | 0.84 | ALDH1A1 (0.50) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL29619390 | 0.83 | ALOX15 (0.65) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL2139103 | 0.83 | ALOX15 (0.65) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL5466480 | 0.81 | MPL (0.44) | ALDH1A1MAPTHPGDMEN1ALOX12 | |
| SCHEMBL6161066 | 0.81 | ALOX15 (0.69) | KDM4EL3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL30237524 | 0.81 | ALDH1A1 (0.55) | KDM4EL3MBTL1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1668009-A1 | HCV INHIBITORS AND METHODS OF USING THEM | Rigel Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005030774-A1 | HCV INHIBITORS AND METHODS OF USING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | KDM4E 3202/4885L3MBTL1 2227/4885ALDH1A1 874/4885 |
| US-20050090521-A1 | HCV inhibitors and methods of using them | HAVCR2, GLS2, EIF2AK2 | KDM4E 3202/4885L3MBTL1 2227/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.